Now On-Demand - DREAMing Beyond Stage IVA: Lung Transplantation and Molecular Surveillance for Lung-Confined NSCLC
The webinar “DREAMing Beyond Stage IVA: Lung Transplantation and Molecular Surveillance for Lung-Confined NSCLC”, presented by Natera, features findings from the Northwestern University lung transplant team behind the groundbreaking DREAM study.
A new frontier: Transplant as a viable option for patients with primary lung Stage IVA cancer - offering a path forward to those who previously had no alternatives. Balancing the risk of recurrence and rejection is complicated for these patients. Particularly because recurrence is a major concern with a 40-50% chance of recurrence after double lung transplant stage IVA NSCLC.
Innovation that makes it possible: With the combined power of Signatera™ and Prospera™, these patients benefit from molecular detection of recurrence with ongoing rejection surveillance to ensure the right balance of immunosuppression.
WEBINAR SPEAKERS:
Ambalavanan Arunachalam, MD
Ankit Bharat, MD, FACS
The content of this recording was developed entirely by our industry partner, Natera. It is not an official educational program of the ISHLT, and therefore is not eligible for CME under the ISHLT.
